LIM 激酶 (LIMK) 是重要的细胞骨架调节剂,在癌症表现和神经疾病中发挥着重要作用。LIMK 家族由两个同源物 LIMK1 和 LIMK2 组成,它们在表达谱、细胞间定位和功能上彼此不同。LIMK 的主要底物是肌动蛋白丝切蛋白,它是肌动蛋白解聚因子 (ADF) 蛋白家族的成员。当被 LIMK 磷酸化时,肌动蛋白丝切蛋白处于失活状态。LIMK 在多种神经发育障碍以及癌症生长和转移中发挥着重要作用。
LIM 结构域激酶 (LIMK1 和 2) 是 Cdc42/Rac-PAK 的底物,并通过在丝氨酸-3 位点磷酸化肌动蛋白丝切蛋白来调节肌动蛋白动力学。这种修饰会使肌动蛋白丝切蛋白的肌动蛋白切断和解聚活性失活。LIMK 还可转位至细胞核内并调节细胞周期进程。LIMK 是 NF2 和其他 Merlin 缺陷型肿瘤的潜在治疗靶点。
LIM kinases (LIMKs) are important cell cytoskeleton regulators that play a prominent role in cancer manifestation and neuronal diseases. The LIMK family consists of two homologues, LIMK1 and LIMK2, which differ from one another in expression profile, intercellular localization, and function. The main substrate of LIMK is cofilin, a member of the actin-depolymerizing factor (ADF) protein family. When phosphorylated by LIMK, cofilin is inactive. LIMKs play a contributory role in several neurodevelopmental disorders and in cancer growth and metastasis.
LIM domain kinases (LIMK1 and 2) are substrate for Cdc42/Rac-PAK, and modulate actin dynamics by phosphorylating cofilin at serine-3. This modification inactivates cofilin’s actin severing and depolymerizing activity. LIMKs also translocate into the nucleus and regulate cell cycle progression. LIMKs are potential therapeutic targets for NF2 and other merlin-deficient tumors.
DB0662 是一种靶向多靶点激酶的 PROTAC 降解剂,作用于 PTK2B、MAPK9、BLK、CSK、LIMK1 等靶点(粉色:PROTAC 靶蛋白配体 (MS-O83584);蓝色:Cereblon 配体 (MS-B42308);黑色:连接子)。
DD-03-156 是一种选择性靶向 CDK17 和 LIMK2 的 PROTAC 降解剂,为开发降解 CDK17 的化学探针提供了一个先进的起点(粉色:CDK17 配体 (MS-S73097);蓝色:VHL 配体 (MS-R95960);黑色:连接子 (MS-X11431))。
© 2026 MolStrong. 保留所有权利。粤ICP备2023004355号
可通过CAS号进行批量搜索,一行一个CAS号